| Covariate | OR | (95% CI) | Covariate | OR | (95% CI) | Covariate | OR | (95% CI) |
---|---|---|---|---|---|---|---|---|---|
A) Dead at follow-up | DRC | Nigeria | Uganda | ||||||
 Unadjusted | RAS use | 1.25 | (0.81–1.93) | RAS use | 2.95 | (1.78–4.90) | RAS use | 0.70 | (0.29–1.74) |
 Adjusteda | RAS use | 1.96 | (0.88–4.35) | RAS use | 2.57 | (1.40–4.73) | n/ac |  |  |
 Adjusted further for referral and post-referral treatment at RHFa | RAS use | 3.06 | (1.35–6.92) | RAS use | 2.16 | (1.11–4.21) | n/ac |  |  |
Referral | Â | Â | Referral | Â | Â | Â | Â | Â | |
Same or next day | Ref. | Â | Same or next day | Ref. | Â | Â | Â | Â | |
Late | 1.21 | (0.71–2.07) | Late, not completed, unknown | 1.58 | (0.72–3.47) |  |  |  | |
Not completed | 0.20 | (0.10–0.39) |  |  |  |  |  |  | |
Unknown | 0.82 | (0.33–2.02) |  |  |  |  |  |  | |
Treatment | Â | Â | Treatment | Â | Â | Â | Â | Â | |
Inj. AS/ART/QU only | Ref. | Â | Inj. AS/ART/QU only | Ref. | Â | Â | Â | Â | |
ACT only | 0.36 | (0.07–1.70) | ACT only | n/a |  |  |  |  | |
Both | 0.13 | (0.07–0.24) | Both | n/a |  |  |  |  | |
None | 1.14 | (0.56–2.33) | None | 5.85 | (1.06–32.35) |  |  |  | |
Unknown | 2.07 | (1.10–3.90) | Unknown | 7.65 | (2.72–21.53) |  |  |  | |
B) Dead or sick at follow-up | DRC | Nigeria | Uganda | ||||||
 Unadjusted | RAS use | 0.84 | (0.65–1.08) | RAS use | 1.95 | (1.27–3.01) | RAS use | 0.40 | (0.33–0.49) |
 Adjustedb | RAS use | 0.75 | (0.51–1.13) | RAS use | 1.62 | (1.01–2.58) | RAS use | 0.57 | (0.43–0.76) |
 Adjusted further for referral and post-referral treatment at RHFb | RAS use | 0.88 | (0.59–1.32) | RAS use | 1.42 | (0.85–2.36) | RAS use | 0.60 | (0.45–0.79) |
Referral | Â | Â | Referral | Â | Â | Referral | Â | Â | |
Same or next day | Ref. | Â | Same or next day | Ref. | Â | Same or next day | Ref. | Â | |
Late | 0.93 | (0.67–1.30) | Late | 3.20 | (1.21–8.42) | Late | 0.85 | (0.55–1.32) | |
Not completed | 0.36 | (0.22–0.60) | Not completed | 2.39 | (1.08–5.29) | Not completed | 0.74 | (0.60–0.91) | |
Unknown | 0.82 | (0.46–1.47) | Unknown | 1.28 | (0.55–2.97) | Unknown | 0.93 | (0.55–1.58) | |
Treatment | Â | Â | Treatment | Â | Â | Treatment | Â | Â | |
Inj. AS/ART/QU only | Ref. | Â | Inj. AS/ART/QU only | Ref. | Â | Inj. AS/ART/QU only | Ref. | Â | |
ACT only | 0.28 | (0.10–0.75) | ACT only | n/a |  | ACT only | 1.06 | (0.68–1.64) | |
Both | 0.40 | (0.29–0.56) | Both | n/a |  | Both | 0.52 | (0.33–0.83) | |
None | 0.89 | (0.53–1.52) | None | 4.58 | (0.97–21.59) | None | 1.34 | (0.77–2.33) | |
Unknown | 1.11 | (0.68–1.80) | Unknown | 3.26 | (1.41–7.51) | Unknown | 1.47 | (0.96–2.26) |